$13.82
7.80% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Viridian Therapeutics Inc Stock price

$13.82
+0.69 5.26% 1M
-5.97 30.17% 6M
-5.35 27.91% YTD
+0.29 2.14% 1Y
+0.24 1.77% 3Y
+4.33 45.67% 5Y
-325.93 95.93% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.00 7.80%
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Key metrics

Market capitalization $1.13b
Enterprise Value $702.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2,343.23
P/S ratio (TTM) P/S ratio 3,758.67
P/B ratio (TTM) P/B ratio 2.71
Revenue growth (TTM) Revenue growth 4.86%
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-337.01m
Free Cash Flow (TTM) Free Cash Flow $-280.35m
Cash position $636.63m
EPS (TTM) EPS $-4.05
P/E forward negative
P/S forward 5,738.42
EV/Sales forward 3,577.46
Short interest 12.96%
Show more

Is Viridian Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Viridian Therapeutics Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy
88%
Hold
12%

Financial data from Viridian Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.30 0.30
3% 3%
100%
- Direct Costs 1.31 1.31
10% 10%
437%
-1.01 -1.01
14% 14%
-337%
- Selling and Administrative Expenses 61 61
29% 29%
20,383%
- Research and Development Expense 274 274
83% 83%
91,177%
-336 -336
42% 42%
-111,897%
- Depreciation and Amortization 1.31 1.31
10% 10%
437%
EBIT (Operating Income) EBIT -337 -337
42% 42%
-112,335%
Net Profit -293 -293
34% 34%
-97,747%

In millions USD.

Don't miss a Thing! We will send you all news about Viridian Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viridian Therapeutics Inc Stock News

Neutral
Business Wire
about 17 hours ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug (“veli”), an intravenously delivered anti-insulin-like growth facto...
Neutral
Business Wire
13 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to veligrotug (“veli”), the company's lead anti-insulin-...
Neutral
Business Wire
15 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2025. “We continue to execute across the portfolio as we work towards subm...
More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office United States
CEO Stephen Mahoney
Employees 143
Founded 2006
Website www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today